Evrópusambandið - íslenska - EMA (European Medicines Agency)

bayer ag  - vardenafíl - ristruflanir - Þvaglát - meðferð við ristruflunum hjá fullorðnum körlum. ristruflanir eru vanhæfni til að ná eða viðhalda hálsbólgu sem nægir til fullnægjandi kynferðislegrar frammistöðu. Í röð fyrir vivanza að vera virkt, kynferðislega örvun er krafist. vivanza er ekki ætlað að nota af konum.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

atnahs pharma netherlands b.v. - ibandrónsýra - beinþynning, eftir tíðahvörf - lyf til að meðhöndla beinsjúkdóma - meðferð beinbrot í tíðahvörf konur á jókst hættan á beinbrot (sjá kafla 5. lækkun í hættu á hryggbrot hefur verið sýnt fram á, virkni á lærlegg háls beinbrot hefur ekki verið staðfest.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vetviva richter gmbh - pentobarbitalum natríum - stungulyf, lausn - 400 mg/ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vetviva richter gmbh - ketaminum hýdróklóríð - stungulyf, lausn - 100 mg/ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vetviva richter gmbh - lidocainum hýdróklóríð - stungulyf, lausn - 20 mg/ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vetviva richter gmbh - procainum hýdróklóríð - stungulyf, lausn - 20 mg/ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vetviva richter gmbh - metamizolum natricum inn; butylscopolamini bromidum nfn - stungulyf, lausn - 500 mg/ml + 4 mg ml

Evrópusambandið - íslenska - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - Æxlishemjandi lyf - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. sjúklingar sem hafa lítil eða mjög lítil hætta á endurkomu ætti ekki að fá viðbótar meðferð. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. nema í nýlega greind langvarandi áfanga cml, það eru ekki stjórnað rannsóknir sýna klínískum gagnast eða jókst að lifa fyrir þessum sjúkdómum.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vetviva richter gmbh - mepivacainum hýdróklóríð - stungulyf, lausn - 20 mg/ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vetviva richter gmbh - miconazolum nítrat; prednisolonum acetat; polymyxinum b súlfat - eyrnadropar/húðdreifa - 5,0 mg/0,5293 mg/23,0 mg/ml